However, their efficacy and ability to treat the sequela of mTBI remains disputed and no FDA-approved drug exists for mTBI
Short KR, Nygren J, Barazzoni R, James Levine A, Nair KS
ClearSilk ClearSilk is often considered the ideal entry point for GLP-1 patients who are new to laser treatments or prefer a gentle, no-downtime, year-round approach
In fact, as well detail in a later section, liraglutide in 2016 became the first GLP-1 agonist shown to reduce cardiovascular events in a dedicated outcomes trial (LEADER) an immensely important finding that added another dimension to its therapeutic profile
It is a solid first step if you are new to GLP-1 therapy and want a proven, steady approach
U., Jemiolo, B., Craig, B